AMICUS THERAPEUTICS, INC. — Director's Dealing 2020

Jan 8, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS, INC. (FOLD)
CIK: 0001178879
Period of Report: 2020-01-06

Reporting Person: Barth Jay (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-01-06	Common Stock	S	6836	$9.2766	Disposed	166411	Direct
2020-01-07	Common Stock	S	9938	$9.356	Disposed	156473	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	20	Indirect

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.09 to $9.38. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $9.17 to $9.47 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.